361 related articles for article (PubMed ID: 16157074)
1. HMG-CoA reductase inhibitors and the kidney.
Campese VM; Hadaya B; Chiu J
Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
[TBL] [Abstract][Full Text] [Related]
2. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?
Campese VM; Nadim MK; Epstein M
J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S11-7. PubMed ID: 15938026
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibitors and the kidney.
Campese VM; Park J
Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867
[TBL] [Abstract][Full Text] [Related]
4. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
[TBL] [Abstract][Full Text] [Related]
5. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
Kanbay M; Turgut F; Covic A; Goldsmith D
J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
[TBL] [Abstract][Full Text] [Related]
6. Effects of statins on renal function.
Agarwal R
Mayo Clin Proc; 2007 Nov; 82(11):1381-90. PubMed ID: 17976359
[TBL] [Abstract][Full Text] [Related]
7. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
Heymann EP; Kassimatis TI; Goldsmith DJ
J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
[TBL] [Abstract][Full Text] [Related]
8. [Chronic kidney disease and statins].
Matovinović MS
Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
[TBL] [Abstract][Full Text] [Related]
9. Statins and renal disease: friend or foe?
Deshmukh A; Mehta JL
Curr Atheroscler Rep; 2011 Feb; 13(1):57-63. PubMed ID: 21053107
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
Scarpioni R; Ricardi M; Melfa L; Cristinelli L
Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function.
Epstein M; Campese VM
Am J Kidney Dis; 2005 Jan; 45(1):2-14. PubMed ID: 15696439
[TBL] [Abstract][Full Text] [Related]
12. [Statins and kidney disease].
Bigazzi R; Grimaldi D; Bianchi S
G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
[TBL] [Abstract][Full Text] [Related]
13. [Statins in chronic renal disease].
Ferreira SR; Rocha AM; Saraiva JF
Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():45-9. PubMed ID: 16400399
[TBL] [Abstract][Full Text] [Related]
14. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
Montague T; Murphy B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
[TBL] [Abstract][Full Text] [Related]
15. Statins in chronic kidney disease and kidney transplantation.
Kassimatis TI; Goldsmith DJ
Pharmacol Res; 2014 Oct; 88():62-73. PubMed ID: 24995940
[TBL] [Abstract][Full Text] [Related]
16. The dyslipidemia of chronic renal disease: effects of statin therapy.
Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
[TBL] [Abstract][Full Text] [Related]
17. ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?
Moradi H; Streja E; Vaziri ND
Semin Dial; 2018 Jul; 31(4):398-405. PubMed ID: 29707830
[TBL] [Abstract][Full Text] [Related]
18. Impact of statins on cardiovascular outcomes in renal transplant recipients: a systematic review.
Maharjan N; Bedi U; Arora R; Bhandari S; Dahal P; Khosla S
Am J Ther; 2011 May; 18(3):e48-54. PubMed ID: 21048435
[TBL] [Abstract][Full Text] [Related]
19. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
20. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
Vaziri ND; Norris KC
Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
